A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors | MicrobiomeTrials← Back to trialsNCT07226349
A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2025-12-11Est. Completion: 2028-11-01
Enrollment target: 105 participants Locations- University of Alabama At Birmingham Hospital, Birmingham, Alabama, United States
- Yale Cancer Center, New Haven, Connecticut, United States
- Sidney Kimmel Comprehensive Cancer At Johns Hopkins, Baltimore, Maryland, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- The University of Texas Md Anderson Cancer Center, Houston, Texas, United States
- Next Oncology Houston, Houston, Texas, United States
- Medical College of Wisconsin, Milwaukee, Wisconsin, United States
- Blacktown Cancer and Haematology Centre, Blacktown, New South Wales, Australia
- Genesiscare St Leonards, St Leonards, New South Wales, Australia
- Icon Cancer Centre Wesley, Auchenflower, Queensland, Australia
- Cabrini Hospital Malvern, Malvern, Victoria, Australia
- Peter Maccallum Cancer Centre, Melbourne, Victoria, Australia
- One Clinical Research, Nedlands, Western Australia, Australia
- Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing Municipality, China
- Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South), Guangzhou, Guangdong, China
Other microbiome trials you might be interested in
Non-Small Cell Lung Cancer (NSCLC)
The primary objectives are to compare progression-free survival (PFS) and overall survival (OS) in participants who rece…
Santa Barbara, United StatesEst. completion Jun 30, 2027
Advanced Solid TumorLocally Advanced Solid TumorMetastatic Solid TumorPlatinum-resistant Ovarian CancerPost Anti-PD-1 Melanoma
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, ChinaTongji Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, ChinaUnion Hospital Tongji Medical College Huazhong University of Science and Technologyjinyinhu Branch, Wuhan, Hubei, ChinaJiangsu Province Hospital Longjiang Branch, Nanjing, Jiangsu, ChinaQilu Hospital of Shandong University, Jinan, Shandong, ChinaWeifang Peoples Hospital, Weifang, Shandong, ChinaRigshospitalet, Copenhagen, Denmark2L+ Cervical Cancer
Neoadjuvant Melanoma
Neoadjuvant Non-Small Cell Lung Cancer
Post Anti-PD-(L)1 Non-Small Cell Lung Cancer
Post Anti-PD-(L)1 Small Cell Lung Cancer
Third Line or Later (3L+) HER2+ Breast Cancer
Second or Third Line (2L/3L) Cervical Cancer
Third-line or Later (3L+) Platinum-resistant Ovarian Cancer (PROC)
TransCon IL-2 β/γ is an investigational drug being developed for treatment of locally advanced or metastatic solid tumor…
Los Angeles, United StatesEst. completion Aug 2027